Great article but hopefully Jason is grossly underestimating PA customers at 800,000 from 24,000,000 market potential in US alone. Especially if 14-19 million already take aspirin?!
If his % acceptance are in fact off......throw in ex-US market, use of Aspririn therapy for other diseases (ie this weeks news it may lower risk of breast cancer reoccurrence, etc..). and his $11/share projection will increase exponentially.
I can't wait for partners PR machine to kick into gear after approval.
Nevertheless - with 800,000 users in US and once 800,000 users in EU we get $500 mill revenue and 20% royalty = 100 million at 30 million shares = 3 usd per share without costs x 15 = share price target of $45.
Thats quite a lot and reason enough to wait for approval in US and partnering for EU and ROW which will furthermore give us some licencing prepayments on hand for cash distributions.
Long position in RXII, LPCN, POZN;
and of course: the US PA user base could also be 2 million and the revenue base $700 million in US alone (at $1 / pill) = 20% thereof = $140 mill / 30 million shares = 4 usd x 15 = 60 usd share price target for US market alone.
Long position LPCN, POZN, RXII;